ciprofloxacin and telavancin

ciprofloxacin has been researched along with telavancin in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (37.50)	29.6817
2010's	4 (50.00)	24.3611
2020's	1 (12.50)	2.80

Authors

Authors	Studies
Jansen, WT; Milatovic, D; Verel, A; Verhoef, J	1
Lombardo, F; Obach, RS; Waters, NJ	1
Benton, BM; Debabov, DV; Difuntorum, S; Krause, KM; Renelli, M; Wu, TX	1
Crandon, JL; Kuti, JL; Nicolau, DP	1
Appelbaum, PC; Ednie, LM; Lin, G; Pankuch, GA	1
Cars, O; Forsberg, P; Giske, CG; Hickman, RA; Lagerbäck, P; Tängdén, T	1
Blaskovich, MAT; Cooper, MA; Gong, Y; Kavanagh, A; Ramu, S	1
Epps, KL; Epps, QJ; Young, DC; Zobell, JT	1

Reviews

1 review(s) available for ciprofloxacin and telavancin

Article	Year
State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics. Pediatric pulmonology, 2020, Volume: 55, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Ciprofloxacin; Clindamycin; Cystic Fibrosis; Humans; Linezolid; Lipoglycopeptides; Methicillin; Methicillin-Resistant Staphylococcus aureus; Rifampin; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin	2020

Article

Year

State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics.

Pediatric pulmonology, 2020, Volume: 55, Issue:1

Topics: Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Ciprofloxacin; Clindamycin; Cystic Fibrosis; Humans; Linezolid; Lipoglycopeptides; Methicillin; Methicillin-Resistant Staphylococcus aureus; Rifampin; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin

2020

Other Studies

7 other study(ies) available for ciprofloxacin and telavancin

Article	Year
In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9 Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Europe; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pyogenes; Vancomycin Resistance; Viridans Streptococci	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:7 Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; In Vitro Techniques; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus; Streptococcus	2008
Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:12 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pneumonia; Staphylococcal Infections; Vancomycin	2010
Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5 Topics: Aminoglycosides; Anti-Bacterial Agents; Cefepime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Drug Synergism; Gentamicins; Lipoglycopeptides; Meropenem; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxacillin; Rifampin; Thienamycins; Time Factors	2010
Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:3 Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Ciprofloxacin; Colistin; Daptomycin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Fosfomycin; In Vitro Techniques; Klebsiella pneumoniae; Lipoglycopeptides; Meropenem; Microbial Sensitivity Tests; Minocycline; Rifampin; Thienamycins; Tigecycline; Vancomycin	2014
Effects of Microplate Type and Broth Additives on Microdilution MIC Susceptibility Assays. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Calcium; Ciprofloxacin; Colistin; Culture Media; Depsipeptides; Escherichia coli; Factor Analysis, Statistical; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxacillin; Penicillin G; Plastics; Polymyxin B; Polysorbates; Rifampin; Teicoplanin; Trimethoprim; Vancomycin	2019